ASH 2018: Dr. Nitin Jain on a fixed duration of Ibrutinib and Venetoclax in Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)

You are here:
Social media & sharing icons powered by UltimatelySocial